Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/13/2026
-
MarketBeat
3/11/2026
-
Ticker Report
3/11/2026
-
MarketBeat
3/11/2026
-
TipRanks Financial Blog
3/11/2026
-
Tickeron - Stocks
3/10/2026
-
Tickeron - Stocks
3/8/2026
-
Simply Wall St
3/7/2026
-
MarketBeat
3/7/2026
-
Tickeron - Technical Analysis
3/7/2026
-
Tickeron - Technical Analysis
3/6/2026
-
Insider Monkey
3/6/2026
-
Yahoo! Finance: News
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Insider Monkey
3/5/2026
-
MarketBeat
3/5/2026
-
Tickeron - Stocks
3/4/2026
-
MarketBeat
3/4/2026
-
Tickeron - Stocks
3/3/2026
-
Simply Wall St
3/3/2026
-
Tickeron - Technical Analysis
3/3/2026
-
Tickeron - Technical Analysis
3/2/2026
-
TipRanks Financial Blog
3/1/2026
-
Simply Wall St
2/28/2026
-
Tickeron - Technical Analysis
2/28/2026
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 272 4600
Address
221 Crescent Street
Waltham, MA 02453
Waltham, MA 02453
Country
Year Founded
Business Description
Sector
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED)...
more